Non Hodgkin's Lymphoma News and Research

RSS

The Non-Hodgkin lymphomas (NHLs) are a diverse group of hematologic cancers which encompass any lymphoma other than Hodgkin's Lymphoma.

Immunomedics awarded U.S. and Australian patents

Immunomedics announced that it has received notices that the U.S. and Australian patent offices have allowed claims in respective patent applications covering methods for treating a wide range of autoimmune diseases using monoclonal antibodies that bind to the CD22 antigen present on B-lymphocytes.

16 Jun 2005

MabThera highly effective in treating rheumatoid arthritis

Results from the DANCER study presented today revealed that MabThera significantly improves symptoms in heavily treated patients who are affected by moderate-to-severe rheumatoid arthritis (RA), a painful and debilitating disease of the joints.

9 Jun 2005

Drinking alcohol may lower risk of developing non-Hodgkin's lymphoma

People who drink alcohol may have a lower risk of developing non-Hodgkin's lymphoma (NHL) - a type of cancer that affects the lymphatic system, suggests a study published online by The Lancet Oncology.

6 Jun 2005

Long-term outcomes studied for stem cell transplant recipients

Improved techniques and supportive care have resulted in a growing number of long-term survivors of stem cell transplants, though little is known about the impact transplants have on patients’ lives long after treatment.

23 May 2005

Antiretroviral therapy may prevent excess risk of some cancers in people with HIV

In people infected with human immunodeficiency virus (HIV), highly active anti-retroviral therapy (HAART) may prevent most excess cases of Kaposi sarcoma and non-Hodgkin lymphoma, according to a new study in the March 16 issue of the Journal of the National Cancer Institute.

18 May 2005

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

Researchers at the Keck School of Medicine of the University of Southern California and colleagues have found a way to streamline a new form of treatment for patients with non-Hodgkin's lymphoma.

18 May 2005

Zevalin safe and effective for non-Hogdkin's lymphoma patients

According to a University of Pittsburgh Medical Center (UPMC) study, patients with advanced non-Hodgkin's lymphoma (NHL) previously treated with chemotherapy and adult stem cell transplantation can safely tolerate Zevalin (ibritumomab tiuxetan), a radiolabeled monoclonal antibody that targets radiation directly to a tumor.

17 May 2005

Key discovery about non-Hodgkin lymphoma

There is a surprise benefit to being either an only child, the oldest sibling or even enduring some allergies – you are significantly less likely to develop non-Hodgkin lymphoma (NHL), according to new research from the University of New South Wales (UNSW).

19 Apr 2005

Antiretroviral therapy may prevent some cancers in people with HIV

In people infected with human immunodeficiency virus (HIV), highly active antiretroviral therapy (HAART) may prevent most excess cases of Kaposi sarcoma and non-Hodgkin lymphoma, according to a new study in the March 16 issue of the Journal of the National Cancer Institute.

15 Mar 2005

Association noted between certain non-lver cancers and hepatitis C

People infected with the hepatitis C virus (HCV) have a higher risk of developing non-Hodgkin's lymphoma and multiple myeloma, according to a recent study of the Swedish population.

22 Feb 2005

FDA knocks back anticancer drug Marqibo

Inex Pharmaceuticals announced today that United States Food and Drug Administration (FDA) provided an action letter detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval regulations based on the phase 2 clinical trial data submitted.

19 Jan 2005

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.

14 Dec 2004

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Results from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated that Zevalin (ibritumomab tiuxetan), administered as a first-line therapy, induced a 100 percent response rate in a small population of patients with low-grate follicular lymphoma (FL).

6 Dec 2004

Bcl-6 oncogene - genetic target for lymphoma treatment

Results from a pre-clinical study show that the gene designated Bcl-6 is an oncogene -- that is, one with the potential to cause a normal cell to become cancerous -- but that certain peptide inhibitors can in effect inactivate it, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Genasense shown to enhance the anti-lymphoma activity of Velcade and Rituxan

Genta Incorporated announced that two new studies have shown that Genasense (oblimersen sodium) Injection, the Company's lead anticancer drug, showed synergistic activity with both bortezomib (Velcade; Millennium Pharmaceuticals, Inc.) and rituximab (Rituxan; Genentech, Idec) in experimental models of B-cell non-Hodgkin's lymphoma (NHL).

5 Dec 2004

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004

Understanding the signals that delay the spread of follicular lymphoma could provide new therapeutic targets

Scientists at the National Cancer Institute (NCI), have created a model that predicts the survival of follicular lymphoma patients based on the molecular characteristics of their tumors at diagnosis.

18 Nov 2004

Some allergic conditions could increase your risk of suffering from blood cancer

Some allergic conditions could increase your risk of suffering from blood cancer as an adult, according to a new study published in the November 2004 issue of BMC Public Health. This is important news for the increasingly large numbers of allergy sufferers worldwide.

4 Nov 2004

People with diabetes mellitus have three to four times the risk of developing liver cancer

People with diabetes mellitus have three to four times the risk of developing liver cancer, and more than twice the risk of developing pancreatic cancer than non-diabetic individuals, according to research presented at the Third Annual Frontiers in Cancer Prevention Research Meeting in Seattle.

18 Oct 2004

Hepatitis C infection increases likelihood of developing non-Hodgkin's lymphoma significantly

Patients infected with the hepatitis C virus (HCV) are six times as likely to develop non-Hodgkin's lymphoma (NHL) than individuals that are virus free, according to research presented at the Third Annual Frontiers in Cancer Prevention Research meeting.

18 Oct 2004